Recent Updates
Recently added Catalysts
KRYS

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

Key Takeaway: PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Hea
Price reaction · baseline $63.65 (2022-05-02 close) · hit after-hours · clean, no other KRYS news in the window
day 0 close · peak
-0.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+100%
120-day peak, hindsight
Typical move
4.2%
average across 5 past catalysts
Lead asset
KB707
Phase 1 · Cancer

Full Press Release Details

PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference.
Details for the event are as follows:
Bank of America Merrill Lynch Global Healthcare Conference
Date: Tuesday, May 10, 2022
Time: 9:20am PDT
Webcast Link: https://bofa.veracast.com/webcasts/bofa/hc2022/id6InQpA.cfm
A webcast of the presentation will be available on the Investors section of the Company’s website for 90 days following the presentation.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing treatment options for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.
Investors and Media:
Source: Krystal Biotech, Inc.
Last updated: May 3, 2022